Browsing Tag
BioLife Solutions
2 posts
Repligen targets up to $852m in 2026 sales as cell therapy acquisition reshapes portfolio
Repligen raises its 2026 sales forecast to $844M–$852M after record quarterly revenue, strong organic growth and its BioLife acquisition.
Wall Street welcomes Repligen’s $1.5bn BioLife deal, but integration now matters
Repligen’s $1.5bn BioLife deal targets recurring cell therapy revenue. See why investors welcomed the bet and where execution risk remains.